Patients with adenomyosis were randomly allocated to receive letrozole, an aromatase inhibitor or goserelin, a GnRH agonist, and outcomes were reported as uterine and adenomyoma volumes at 4, 8 and 12 weeks. This evidence concerns the gene CYP19A1 and adenomyoma.